(Total Views: 713)
Posted On: 09/17/2025 10:22:26 PM
Post# of 157138
Observation from yesterday's press release...
All previous CytoDyn press releases opened with the following:
"...a clinical-stage biotechnology company advancing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications..."
However yesterday's press release had some tweaks to the opening section ("oncology" company rather than "biotechnology" company being one of the key changes along with additional new language regarding breast cancer and colon cancer):
"...a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC)..."
______________________________
I remain... #BULLISH
All previous CytoDyn press releases opened with the following:
"...a clinical-stage biotechnology company advancing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications..."
However yesterday's press release had some tweaks to the opening section ("oncology" company rather than "biotechnology" company being one of the key changes along with additional new language regarding breast cancer and colon cancer):
"...a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC)..."
______________________________
I remain... #BULLISH
(33)
(0)
